4SC enters into licensing and development partnership with Link Health for the cancer compound 4SC 205 in China

DGAP-News: 4SC AG / Key word(s): Alliance

2016-05-31 / 07:30
The issuer is solely responsible for the content of this announcement.

4SC enters into licensing and development partnership with Link Health for the cancer compound 4SC-205 in China

Link Health will be responsible for clinical development and regulatory process for 4SC-205 in China whereas 4SC will receive upfront, milestone and royalty payments

Planegg-Martinsried, Germany / Guangzhou, China, 31 May 2016 – 4SC AG (4SC, FSE Prime Standard: VSC) has entered into a licensing and development partnership for the cancer compound 4SC-205 with Guangzhou LingSheng Pharma Tech Co., Ltd (Link Health). Link Health will receive the exclusive licensing rights for the development and marketing of 4SC-205 in China, Hong Kong, Taiwan and Macao. In return, Link Health will be responsible for performing and financing the clinical development of 4SC-205.

After successfully completing the clinical studies, Link Health will be responsible for regulatory approval at the CFDA (China Food and Drug Administration) and regional product marketing. The data generated may be used by 4SC to support further development of 4SC-205 in other key markets, such as Europe or the US.

Under the agreement, 4SC will receive upfront and milestone payments totaling up to EUR 76 million from Link Health payable upon achieving specified development, regulatory and commercialization milestones. In addition, 4SC will be eligible to double-digit royalties linked to product sales of 4SC-205 in China.

“We are very pleased to partner with Link Health having in-depth expertise in the clinical development, approval process and marketing of oncology products in this important Asian market,” comments Enno Spillner, CEO & CFO of 4SC. “Having shown promising results in the Phase I study in patients with advanced cancer, this partnership is an important step to ensure efficient further development of the cancer drug 4SC-205. On the other hand, in line with its strategic focus, 4SC can use its own financial resources for development of the epigenetic products resminostat and 4SC-202. In parallel, we are looking for further development and licensing opportunities for 4SC-205.”

Dr Yan Song, CEO of Link Health, says: “We are proud to be given the opportunity to take over this innovative cancer product for our region and are planning an extensive clinical development program. Thanks to the promising preclinical and clinical data on 4SC-205, we have high hopes for this cancer drug and look forward to a productive and value-adding partnership.”

– End of press release –

Further information

About 4SC-205

4SC-205 is a cancer compound that inhibits the so-called “kinesin spindle protein” Eg5, which plays a key role in cell division and therefore the growth of cancer cells. Cell division inhibitors are deployed with great success in oncology, although they have serious side effects. Due to 4SC-205’s special mode of action, the compound does not cause such side effects. To the best of the Company’s knowledge, 4SC-205 is the only Eg5 inhibitor available as a tablet that is currently in clinical development. In a Phase I study, the substance has already shown to be safe and well-tolerated in different dosing schemes. Additionally, initial indications of efficacy were determined.

About 4SC

4SC (www.4cs.com) is a biotechnology company dedicated to the research and development of small-molecule drugs focused on epigenetic mechanisms of action for the treatment of cancers with high unmet medical needs. These drugs are intended to provide innovative treatment options for cancer patients that are more tolerable and efficacious than existing therapies, provide a better quality of life and offer increased life expectancy. The Company’s pipeline comprises promising products that are in various stages of clinical development. 4SC’s aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies. Founded in 1997, 4SC had 50 employees at 1 May 2016. 4SC has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

About Link Health

Link Health is a high-quality pharmaceutical company focused on licensing, registration, clinical study and regulatory consulting services in the Greater China area. Link Health aims at unveiling and promoting innovative drugs, which are made to address crucial medical needs. Based on several years’ experience in the pharmaceutical industry, Link Health created a strong team to provide solutions for regulatory, (pre)clinical research, licensing, partnering and communications (IND, NDA applications) with the CFDA (China Food and Drug Administration), among others. Link Health has expertise in the licensing and co-development of INDs and devices at clinical stage.

Operating from the Chinese market, Link Health specializes in linking businesses from different markets to the mutual benefit of each other. The professional teams target and screen the best innovations in medical industry with the aim of creating market value in China with local partners. More information can be found at: www.healthinlink.com.

Forward-looking information

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward looking statements. No warranties or representations are made as to the accuracy, achievement or reasonableness of such statements, estimates or projections, and 4SC AG has no obligation to update any such information or to correct any inaccuracies herein or omission herefrom which may become apparent.

Related articles

3 June 2015, 4SC presents final results from Phase I AEGIS trial as well as rationale for daily dosing scheme of 4SC-205 cancer compound at ASCO

13 August 2015, 4SC strengthens patent protection for its epigenetic cancer drug candidate 4SC-202 in growth market China

Contact

4SC AG
Corporate Communications & Investor Relations
Wolfgang Güssgen, email hidden; JavaScript is required, +49 89 700763-73
Dr. Anna Niedl, email hidden; JavaScript is required, +49 89 700763-66

MC Services
Katja Arnold, email hidden; JavaScript is required, +49 89 210228-40

The Ruth Group
Carol Ruth, email hidden; JavaScript is required, +1 646 536 7004

Share this page:

Follow us on: